Bio-Europe Conference

Day 2 and SUDA must be flat out talking to companies. Looking at the website for the conference the average number of meetings for the 2 and a half days is 21. As Suda indicated they are in half hour discussions with over 40 companies. That is at least 20 hours of meeting in 2 and a half days. If Suda has twice the number of the average it would be logical to conclude that there is a lot of interest out there in regards to their technology and products.

From the ASX release there are a number of positives as I see it.
Companies are not only interested in the clinical stage oral sprays but also in the technology that delivers it. This can only mean that some companies are interested in using the technology for their own products .-how many products and how much are they prepared to pay?

The fact that a number of companies are having ongoing discussions from 12 months ago has to be a positive and takes them one step closer to finalizing a deal. If they weren't interested they would have walked away by now.

Zolpimist is on the table having FDA approval. This has to be attractive to companies outside the US. (Suda does not have rights to the US market)

Interest from GLOBAL pharmaceutical companies in their pipeline of products as well as their technology.

and the last comment - we are working hard to FINALIZE deals- not to initiate deals but to finalize.

Looking forward to getting some feedback from the company and progress toward finalization of some deals.